Ceramides are sphingolipid second messengers that are involved in the mediation of cell death. There is accumulating evidence that mitochondria play a central role in ceramide-derived toxicity. We designed a novel cationic long-chain ceramide [W-pyridinium bromide D-erythro -C 16 -ceramide (LCL-30)] targeting negatively charged mitochondria. Our results show that LCL-30 is highly cytotoxic to SW403 cells (and other cancer cell lines) and preferentially accumulates in mitochondria, resulting in a decrease of the mitochondrial membrane potential, release of mitochondrial cytochrome c, and activation of caspase-3 and caspase-9. Ultrastructural analyses support the concept of mitochondrial selectivity. Interestingly, levels of endogenous mitochondrial C 16 -ceramide decreased by more than half, whereas levels of sphingosine-1-phosphate increased dramatically and selectively in mitochondria after administration of LCL-30, suggesting the presence of a mitochondrial sphingosine kinase. Of note, intracellular long-chain ceramide levels and sphingosine-1-phosphate remained unaffected in the cytosolic and extramitochondrial (nuclei/cellular membranes) cellular fractions. Furthermore, a synergistic effect of cotreatment of LCL-30 and doxorubicin was observed, which was not related to alterations in endogenous ceramide levels.
Introduction
Ceramides have emerged as important lipid second messengers involved in cell growth, differentiation, senescence, and death (1) . The intracellular levels of this sphingolipid are elevated in tumor cells after irradiation or therapy with anticancer drugs, such as doxorubicin (2) , implicating endogenous ceramides as important mediators of cancer therapy (3) . It has also been shown that exogenous ceramides induce cell death in a variety of human cancer cell types (4) . Interestingly, cancer cells seem to be more susceptible to the toxic effect of exogenous ceramides than normal cells (5 -7), rendering exogenous ceramides promising novel drugs for chemotherapy.
There is accumulating evidence that mitochondria play a central role in ceramide-derived cell death. Studies on isolated mitochondria revealed that ceramides released cytochrome c from mitochondria (8) (9) (10) , and ceramide was reported to activate a mitochondrial protein phosphatase 2A, which dephosphorylates the antiapoptotic Bcl-2 molecule and leads to cell death (11) . Furthermore, indirect modification of Bcl-2 by ceramide was also reported by targeting the nonmitochondrial cathepsin D (12) . Targeting of sphingomyelinase to mitochondria, but not other subcellular compartments, resulted in translocation of Bax and activation of the mitochondrial pathway of apoptosis (13) . Moreover, ceramide-metabolizing enzymes have also been detected in mitochondria, and these include neutral/alkaline ceramidase (14) and ceramide synthase (15) . Functionally, ceramide was shown to block mitochondrial respiratory chain complex I/III by a direct interaction (9, 16) ; finally, ceramide has been shown to induce the production of reactive oxygen species (ROS) in intact mitochondria (8) .
Mitochondria from cancer cells and from normal cells differ in many aspects, offering mitochondria as potential targets for cancer therapy. First, the metabolism of cancer cells is characterized by an increased anaerobic glycolysis that is not influenced by the oxygen concentration rendering cancer cells resistant to hypoxia (Warburg effect). Secondly, differences in the permeability transition pore complex from cancer versus normal cells have been repeatedly described (17 -19) . Furthermore, the mitochondrial membrane potential (Dc m ) is higher in cancer compared with normal cells (20) .
Cationic lipophilic molecules accumulate within the mitochondrial matrix driven by the electrochemical gradient, which could favor increased accumulation in mitochondria of cancer cells. Positively charged short-chain (C 6 ) ceramides were shown to be enriched in mitochondria and to induce cell death (10) . Because naturally occurring ceramides have an acyl chain of z14 carbon atoms, we designed a novel cationic N-pyridinium bromide D-erythro -C 16 -ceramide (LCL-30) and investigated (a) its toxicity, (b) its intracellular distribution, and (c) the influence of this long-chain ceramide on endogenous ceramide levels in SW403 human colon cancer cells. As doxorubicin is also a cationic lipophilic molecule and has been shown to exert at least some of its toxicity by interference with the endogenous ceramide levels, we tested the combined effects of LCL-30 with doxorubicin.
Materials and Methods
Synthesis and Solubilization of the Ceramide Analogue LCL-30
Cationic LCL-30 was synthesized in the Medical University of South Carolina Lipidomics Core. 4 For experimental use, LCL-30 was dissolved in ethanol to 10 mmol/L stock solutions and kept at À20jC.
Cell Culture and Biological Reagents SW403 human colon carcinoma cells (CCL-230; American Type Culture Collection, Manassas, VA) were cultured in DMEM (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (PAA Laboratories GmbH, Cö lbe, Germany) and 100 units/mL penicillin and 100 Ag/mL streptomycin (Life Technologies). The cells were maintained at 37j C in a 5% CO 2 atmosphere. C 2 -and C 6 -ceramides were purchased from Avanti Polar Lipids (Alabaster, AL). C 16 -ceramide, actinomycin D, rotenone, N-acetylcysteine, and cyclosporine A were from Sigma (St. Louis, MO). Recombinant human tumor necrosis factor-a was purchased from R&D Systems (Minneapolis, MN). Caspase-3 and caspase-9 substrates (Ac-DEVD-AFC and Ac-LEHD-AFC, respectively) as well as pan-caspase inhibitor (Z-VAD-FMK) were from Alexis Biochemicals (Lausen, Switzerland). Doxorubicin HCl (Sigma) was dissolved in 0.9% NaCl and kept at 4jC.
Cell Viability Assay Cells were seeded into 12-well plates at a density of f50% corresponding to 0.5 Â 10 6 per well, left to adhere overnight, and subjected to the specified conditions for a period of 12 or 24 hours. Then, medium was changed and the number of viable cells was assessed by the addition of 40 AL of a 0.5% tetrazolium salt solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT); Sigma]. After 60 minutes of incubation, the formation of the formazan product was monitored by measuring absorbance at 570 nm after solubilization in acidic isopropranol (5% formic acid in isopropranol). Values were calculated as percentage of untreated controls. In all conditions, cells were exposed to ethanol in a nontoxic concentration of 0.05% (v/v). In parallel, cells were incubated as described above. Cells were then detached using 1% trypsin and centrifuged at 800 Â g. Cell pellets were resuspended in PBS, and trypan blue (Sigma) staining was assessed by light microscopy.
Caspase-3/Caspase-9 Activity SW403 cells were cultured under the specified conditions, and caspase activity was measured after 12 hours of incubation. Adherent cells were scraped and lysed [10 mmol/L Tris-HCl (pH 7.4), 2 mmol/L EDTA, 0.1% NP40] for 10 minutes at 4jC. After centrifugation for 10 minutes at 10,000 Â g, protein concentration was measured using the Bio-Rad detergent-compatible protein assay (Bio-Rad Laboratories, Hercules, CA). Lysate corresponding to 25 Ag protein was incubated for 30 minutes at room temperature with or without 1 Amol/L pancaspase inhibitor Z-DEVD-FMK. Then, caspase-3 substrate Ac-DEVD-AFC (10 Amol/L) or caspase-9 substrate Ac-LEHD-AFC (10 Amol/L), and DTT (10 mmol/L final concentration) were added, and enzyme activity was monitored by measuring fluorescence at 390 ex /538 em nm (Biolise software, Fluostar SLT-Labinstruments, Crailsheim, Germany). Caspase activity was then calculated by determining the relative fluorescence units generated under steady-state kinetics from which values of caspaseindependent protease activity in the presence of the corresponding inhibitor were subtracted.
Terminal Deoxynucleotidyl Transferase^Mediated dUTP Nick End Labeling Staining SW403 cells were cultured under the specified conditions, trypsinized, and resuspended in culture medium (1 Â 10 6 /mL). An aliquot (100 AL) of the cell suspension was centrifuged in a Shendon Cytospin III at 500 rpm for 2 minutes (ThermoShendon, Pittsburgh, PA). Slides were air-dried for 30 minutes and then stored at À80jC. Slides were thawed at room temperature, washed with PBS, and placed in methanol/H 2 O 2 (2%) for 8 minutes. After washing with PBS, cells were permeabilized with Tri-X buffer (0.1% Triton X, 0.1% sodium citrate in H 2 O) for 2 minutes on ice, washed again with PBS, stained with terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling reaction mixture (In situ Cell Death Detection kit, Roche Diagnostics GmbH, Mannheim, Germany), and incubated for 30 minutes at 60jC.
Measurement of Intracellular Doxorubicin Concentration
For determination of cellular doxorubicin uptake, cells were trypsinized and washed with ice-cold PBS. The pellet was resuspended with 100 AL ice-cold PBS and then mixed for 30 seconds with 500 AL chloroform/methanol (4:1, v/v). After centrifugation with 1,200 Â g for 15 minutes, 100 AL of the organic phase were removed and endogenous fluorescence of doxorubicin was measured in a fluorescence spectrophotometer 470 ex /585 em nm (Fluostar).
Determination of #Y m SW403 cells were maintained in flasks (25 cm 2 ) and cultured at the specified conditions. Cells were then washed in PBS, and fresh cell medium supplemented with MitoTracker (Molecular Probes, Inc., Eugene, OR) was added according to the manufacturer's instructions. After 30 minutes, cells were washed in PBS and trypsinized. After resuspension in PBS, cells were analyzed by flow cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ).
Western Blot Analysis for Cytochrome c
For analysis of cytochrome c release, cells were trypsinized and washed with ice-cold PBS. Mitochondrial and cytosolic (S100) fractions were prepared from cells suspended in 50 AL ice-cold buffer containing 20 mmol/L HEPES-KOH (pH 7.5), 10 mmol/L KCl, 1.5 mmol/L MgCl 2 , 1 mmol/L sodium EDTA, 1 mmol/L DTT, 0.1 mmol/L phenylmethylsulfonyl fluoride, and 250 mmol/L sucrose. Mechanical homogenization was achieved by repeated aspiration through a pipette. Cells and nuclei that were not lysed were pelleted by 10 minutes of centrifugation (750 Â g, 4jC). The supernatant was centrifuged at 10,000 Â g for 15 minutes at 4jC. The resulting pellet, representing the mitochondrial fraction, was then resuspended in 10 AL of the buffer described above. Finally, the supernatant was centrifuged at 100,000 Â g for 1 hour at 4jC. Both fractions were stored at À80jC until used. Mitochondrial and cytosolic fractions were diluted in sample buffer [187.5 mmol/L Tris-HCl (pH 6.8), 6% SDS, 30% glycerol, 150 mmol/L DTT, 0.3% bromophenol blue] and then boiled for 10 minutes at 90jC. Samples were run on 16% Novex Tris-glycine gel (Life Technologies), blotted onto polyvinylidene difluoride membrane, and incubated with a mouse anti -cytochrome c monoclonal antibody (PharMingen, San Diego, CA).
Glutathione Determination Cells were cultured in 25-cm 2 flasks and treated with the indicated substances. After washing with PBS, intracellular glutathione (GSH) levels were determined with a GSH kit (Oncogene, San Diego, CA) according to the manufacturer's instructions.
Transmission Electron Microscopy SW403 cells were prefixed with 1.5% glutaraldehyde and 0.8% paraformaldehyde (0.1 mol/L cacodylate buffer) for 30 minutes at room temperature and postfixed in an aqueous solution of 1% OsO 4 + 1.5% K 4 (FeCN) 6 for 1 hour. The specimens were then embedded into Epon by routine procedure. Semithin sections (f1 Am) were stained with toluidine blue and analyzed by light microscopy. Ultrathin sections (f50 nm) were contrasted with lead citrate and uranyl acetate and studied with a Philips CM100 transmission electron microscope (Zurich, Switzerland).
Analysis of Endogenous Ceramide Species by Liquid Chromatography-Mass Spectrometry
Electrospray ionization-tandem mass spectrometry analysis of endogenous ceramide species was done in the Medical University of South Carolina Lipidomics Core on a Thermo Finnigan (Waltham, MA) TSQ 7000 triple quadrupole mass spectrometer, operating in a multiple reaction monitoring -positive ionization mode. Briefly, cell pellets corresponding to f2 Â 10 6 to 3 Â 10 6 cells were fortified with the internal standards and lipids were extracted and analyzed as described. 5 
Statistical Analysis
Data are mean F SD of n independent experiments. MannWhitney U test and one-way ANOVA were used where appropriate. P < 0.05 was considered statistically significant.
Results
Is Cationic LCL-30 Toxic to Cancer Cells? The first set of experiments was to determine cytotoxicity of the novel cationic long-chain ceramides. SW403 cells were cultured in the presence of LCL-30 at concentrations of 1 to 5 Amol/L for 12 and 24 hours. Cell viability was assessed by the MTT assay ( growth, we also tested cell viability by trypan blue exclusion. These results supported the findings of the MTT assay (data not shown). Similar findings by MTT and trypan blue exclusion test were obtained in the colon cancer cell lines LoVo and CT26 and in the human hepatoma cell lines HepG2, Hep3B, and HuH7 (data not shown). Interestingly, no toxicity of LCL-30 could be observed in freshly isolated rat hepatocytes. Cytotoxicity was also evaluated by terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling assay identifying nuclear DNA fragmentation from which the results underscore the toxic effect of LCL-30 (see below). For further analyses, we concentrated on the human colon cancer cell line SW403 because previous work by our group was also done in this cell line (7) .
Does Cationic LCL-30 Preferentially Accumulate in Mitochondria?
Mitochondria of SW403 cells that had been incubated with LCL-30 (5 Amol/L) for 0.5, 1, 2, 4, and 8 hours were isolated. The cytosolic fraction and the extramitochondrial cellular fraction were also used for liquid chromatographymass spectrometry analysis. In the cytosolic fraction, no increase of LCL-30 could be detected. LCL-30 preferentially accumulated in the mitochondria and, to a much lesser extent, in the extramitochondrial fraction, mainly constituting cellular membranes and nuclei (Fig. 2) . After 8 hours of treatment, LCL-30 concentration in mitochondria reached 1.4 pmol/Ag protein, whereas in the extramitochondrial fraction it was at 0.6 pmol/Ag protein. Twenty percent of the total LCL-30 per sample was detectable within the mitochondrial fraction (1,250 versus 6,300 pmol/ sample). The difference in volume of these two fractions further underscores the relative selectivity of LCL-30 accumulation within mitochondria.
Does Cationic LCL-30 Exert Mitochondrial Toxic Effects?
Breakdown of Dc m and cytochrome c release was suggested as the primary pathway mediating cell death in ceramide-treated cells (21) . The disruption of Dc m has been identified as point-of-no-return of cell death because respiration is blocked as soon as Dc m decreases and cytochrome c is released.
In our study, Dc m was determined by the fluorochrome CMXRos in SW403 cells treated with the cationic ceramide LCL-30 (5 Amol/L). A drop in Dc m was observed by flow cytometry in LCL-30-treated cells as early as after 4 hours of treatment (Fig. 3A) , which was accompanied by mitochondrial release of cytochrome c into the cytosol (Fig. 3B) . For the latter analysis, doxorubicin served as positive control.
The decrease of Dc m may be related to the opening of mitochondrial membrane permeability transition pores, which can be inhibited by cyclosporin A (22) . In our study, cyclosporin A (1 Amol/L) did not maintain Dc m , suggesting that mitochondrial transition pores were not involved in LCL-30-induced breakdown of Dc m (Fig. 3A) . Cyclosporin A -insensitive mechanisms for ceramideinduced collapse of Dc m have been postulated by others (9, 23, 24) .
Ceramide may induce oxidative damage by ROS generation of mitochondria (25) or by inhibiting the ROS (8), although conflicting data have been reported (26 -28) . We determined intracellular GSH levels after treatment of SW403 cells with LCL-30 (Fig. 4) . After 12 hours of treatment, no decrease in GSH was observed. To support this finding, cells were pretreated with the selective complex I inhibitor rotenone (5 Amol/L), which blocks ROS generation from mitochondria (29) , and N-acetylcysteine (100 Amol/L), a reducing agent and a precursor of GSH. Rotenone and N-acetylcysteine did not improve cell survival as assessed by MTT assay, supporting that mitochondrial ROS are not involved in cationic longchain ceramide toxicity (data not shown).
Cellular morphology has been used as a criterion to discriminate apoptotic from necrotic cell death. Although biochemical markers indicated an apoptotic form of programmed cell death in our study, transmission electron microscopy was used to further elucidate the type of cell death. Mitochondria, endoplasmic reticulum, nuclear membrane, and chromatin were examined after 4, 12, and 24 hours of treatment. Untreated SW403 cells were characterized by large nuclei and were rich in mitochondria and lipid droplets. After incubation with cationic ceramide, morphology changed significantly, showing cell swelling with loss of microvilli and nuclei with condensed chromatin (Fig. 5 ), although these nuclear alterations did not include any fragmentation of the nucleus. These data are in line with other studies (30, 31) , showing only slight nuclear changes in ceramide-treated cells. However, mitochondria were markedly swollen with increase in mitochondrial matrix volume and unfolded cristae (Fig. 5) . The inner membrane was apparently intact, whereas the outer The nucleus contained dense chromatin, whereas nuclear fragmentation was absent, although the nucleus was highly lobulated. Magnification, Â44,000.
C, control; D, LCL-30 (5 Amol/L).
After LCL-30 treatment, mitochondria were highly distended with destruction of the inner mitochondrial matrix. Outer mitochondrial membrane was disrupted in many mitochondria. Of note, nuclear membrane was intact, although mitochondria were highly destroyed (D). membrane seemed to be ruptured in most of the mitochondria. These changes were already apparent after 4 hours of treatment. Of note, after 24 hours of treatment, nuclear and plasma membranes were still preserved in most of the cells despite the destruction of most of the mitochondria. No membrane blebbing could be observed. Moreover, the endoplasmic reticulum was not enlarged, and ribosomes of the rough endoplasmic reticulum were not detached. This is in contrast to a study showing alterations of endoplasmic reticulum to be the first sign in C 2 -ceramide-treated PC12 cells (30) . Thus, ultrastructural morphology suggests mitochondria to be the primary target of cationic LCL-30 in SW403 cells.
Does Cationic LCL-30 Affect Endogenous Ceramide Levels?
Endogenous ceramide levels were studied after treatment of SW403 cells with LCL-30 (5 Amol/L) at various time points. The cytosolic, mitochondrial, and extramitochondrial (nuclei and cellular membranes) fractions were analyzed. No change of total ceramide levels was found within 8 hours of treatment in the cytosolic and extramitochondrial fractions. These findings were also obtained from analyses of C 14 , C 16 , C 18 , C 18:1 , C 20 , C 24 , and C 24:1 levels. However, total endogenous ceramide levels decreased in the mitochondrial fraction in a timedependent manner (Fig. 6A ). This decrease was accounted for by a selective drop of mitochondrial C 16 -ceramide because the levels of C 14 -, C 18 -, C 18:1 -, C 20 -, C 24 -, and C 24:1 -ceramide in mitochondria remained unaffected. C 16 -ceramide is the most abundant ceramide in many cell types as it is in SW403 cells: C 16 -ceramide constituted almost half of the total endogenous ceramide concentration. Importantly, the total of mitochondrial C 16 -ceramides representing endogenous C 16 -ceramide and the exogenous cationic LCL-30 increased over time (Fig. 6B) .
We also determined endogenous levels of the ceramide metabolites sphingosine and sphingosine-1-phosphate (S1P). Sphingosine may occur in the early stage of apoptosis and may also represent a mediator of cell death. Sphingosine can be phosphorylated by sphingosine kinases to form S1P, which has antiapoptotic properties and may antagonize ceramide-mediated cell death (32) . Endogenous levels of sphingosine remained unaffected by LCL-30 in all of the cellular fractions. In contrast, S1P significantly increased over time in the mitochondrial but not in the cytosolic and extramitochondrial fractions (Fig. 6C) . In untreated cells, S1P was below detection limits in all fractions analyzed.
Does the Coadministration of Doxorubicin Enhance Cell Toxicity of Cationic LCL-30?
Doxorubicin is a commonly used chemotherapeutic agent from the family of the anthracyclines. Like LCL-30, doxorubicin is a lipophilic cationic molecule that may compromise mitochondrial integrity (33) . There is strong evidence that doxorubicin increases endogenous ceramide levels in cancer cells by either activation of neutral sphingomyelinase and/or induction of the de novo pathway of ceramide metabolism (2, 34 -38) . The IC 50 of doxorubicin in the SW403 cell line was 2.5 F 0.3 Amol/L. When doxorubicin was added in a 1 Amol/L concentration to 5 Amol/L LCL-30, the response was enhanced. Survival decreased from 57.3 F 8.8% to 35.6 F 0.8% within 24 hours of treatment as assessed by MTT assay (Fig. 7A) . To differentiate whether enhanced cell death in response to LCL-30 in combination with doxorubicin was additive or synergistic, we employed the fractional product method [fu(1,2) = fu(1) Â fu (2) a synergistic effect between doxorubicin and LCL-30 (Fig. 7B ). This synergistic effect was also reflected by results of caspase-3 and caspase-9 (Fig. 7C) and the terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling assays (Fig. 7D) .
To test the possibility that the novel cationic long-chain ceramide facilitated doxorubicin uptake, intracellular doxorubicin concentrations were measured at various time points (0.5, 1, 2, and 3 hours). Doxorubicin uptake was not altered by the addition of LCL-30 within this time period. Surprisingly, doxorubicin did not affect endogenous ceramide levels in SW403, either. Levels of C 14 -C 24 and levels of the ceramide metabolites sphingosine and S1P remained unchanged in all the three fractions analyzed.
Discussion
In this study, we developed a novel long-chain ceramide analogue and showed that it is highly cytotoxic to cancer cells by mitochondrial targeting. The cationic pyridinium C 16 -ceramide LCL-30 preferentially accumulated in mitochondria, resulting in breakdown of Dc m , release of the proapoptotic cytochrome c, and activation of caspase-9 and caspase-3. Endogenous mitochondrial ceramide levels decreased after treatment with LCL-30, whereas the ceramide levels remained unaltered in the extramitochondrial and cytosolic fractions. S1P, which is known to have antiapoptotic properties, dramatically increased exclusively within mitochondria. Furthermore, this ceramide analogue acted synergistically with doxorubicin in the induction of cell death. This effect was not related to an enhanced uptake of doxorubicin or an increase of endogenous ceramide levels.
A novel chemotherapeutic approach is based on cytotoxic molecules that directly target mitochondria of cancer cells, thereby circumventing upstream proapoptotic pathway that might be mutated or lacking. The mitochondrial membrane permeabilization is considered to be the pointof-no-return in the cell death program. The breakdown of Dc m results in the release of proapoptotic molecules, such as cytochrome c, from mitochondria into the cytosol, activating the cell death machinery. Several findings suggest that the composition and function of normal and cancer cells differ. These include a higher Dc m , possibly modulation of expression of permeability transition pore complex components, enhanced rates of ATP generation through glycolysis rather than through oxidative phosphorylation (the Warburg effect), and a higher susceptibility to oxidative stress by a higher endogenous level of ROS (17 -20, 39) . There is strong evidence that mitochondria are one of the major targets of exogenous ceramides (40) rendering ceramides promising new drugs for cancer therapy.
Because natural, long-chain ceramides are not watersoluble and do not penetrate cellular membranes, synthetic short-chain ceramides (C 2 -and C 6 -ceramides) have been developed to study the biological behavior of ceramide. However, whether the effects of short-chain ceramides fully mimic those of naturally occurring long-chain ceramide species remains unclear. Short-chain ceramides also exhibit different partitioning and behavior in biomembranes (e.g., localization to the Golgi apparatus or the endoplasmic reticulum; refs. 41 -43) . Furthermore, many of the studies were done using isolated mitochondria. In the endoplasmic reticulum, C 2 -ceramide inhibits the biosynthesis of phosphatidylcholine and phosphatidylethanolamine (44, 45) . The inhibition of phospholipid synthesis may block vesicular trafficking and may directly cause apoptosis (46) . To circumvent these shortcomings, we developed a novel cationic long-chain (C 16 ) ceramide (LCL-30), directly targeting the negatively charged mitochondria and creating a tool to investigate the biological effects of naturally occurring long-chain ceramide species.
The cationic long-chain ceramide compound LCL-30 induced cell death in SW403 cancer cells. Analysis of the cellular ceramide pool revealed a decrease of the total endogenous ceramide concentration in LCL-30-treated cells, which is in sharp contrast to other reports using short-chain ceramides. For example, after administration of C 6 -ceramide, the endogenous ceramide pool was shown to increase in HepG2 in Chinese hamster ovary cells (47) and in lung adenocarcinoma A549 cells (48) . Total ceramide and sphingosine levels also increased in Jurkat cells after treatment with C 2 -ceramide (49) . This observation supports the concept that exogenous short-and long-chain ceramides differ in many aspects. Interestingly, the decrease of endogenous ceramide concentration in our study is explained by the selective reduction of the ceramide concentration in mitochondria because no change of the ceramide pool was detected in the extramitochondrial (nuclei/plasma membranes) and cytosolic fractions, respectively. Moreover, only the most abundant ceramide species C 16 and C 24:1 were affected, whereas the other ceramides (C 14 , C 18:0 , C 18:1 , C 20 , and C 24 ) remained unaffected in all of the three cellular fractions. The decline of the proapoptotic endogenous ceramides C 16 and C 24:1 might be interpreted as a defense mechanism of the mitochondrion attacked by a long-chain ceramide. The lack of an increase in total ceramide level after long-chain ceramide administration is in line with recent data showing that apoptotic activity of soluble analogues of C 16 -ceramide did not rely on endogenous ceramide elevation before cell death (50) . Unlike ceramide analogues causing an increase in endogenous ceramide levels [e.g., short-chain ceramides, B13 (7)], the effects of the cationic long-chain ceramides may not be circumvented by activation of ceramide metabolism. Such an increased capacity to metabolize ceramides has been shown for cancer cells (34, 51) leading to resistance to radiation or chemotherapy. Thus, by bypassing ceramide metabolism, these novel compounds have an additional advantage in cancer therapeutics.
Ceramide can be metabolized by ceramidase producing the proapoptotic sphingosine, which in turn may be phosphorylated by sphingosine kinases to form S1P. To date, two isoforms of sphingosine kinases are known, SphK1 and SphK2. Conversely, S1P has been implicated as signaling molecule that antagonizes apoptotic cell death. The dynamic balance among ceramide, sphingosine, and S1P seems to determine survival of the cell. S1P is a specific ligand of a family of five G-proteincoupled cell surface receptors (S1P [1] [2] [3] [4] [5] ). On stimulation, signaling cascades implicated in apoptosis, such as cytochrome c release from mitochondria, activation of caspases, and activation of the stress-activated protein kinase c-Jun NH 2 -terminal kinase, may be inhibited (reviewed in ref. 32 ). This also holds true for ceramidemediated apoptosis, which was reported to be suppressed by S1P (52) .
We observed that LCL-30 induced a selective upregulation of S1P in mitochondria of SW403 cells, whereas S1P levels in cytosol and the extramitochondrial cellular fraction remained unaltered. Along with the decrease of mitochondrial ceramide levels, the increase of S1P likewise implies a mitochondrial defense mechanism in response to mitochondriotoxic agents. The observed alterations of mitochondrial S1P allude to the presence of a mitochondrial sphingosine kinase, which is selectively activated on treatment with exogenous ceramides.
Doxorubicin is a cationic lipophilic molecule as LCL-30, which is suggested to accumulate in mitochondria. When SW403 cells were cotreated with LCL-30 and doxorubicin, we observed a synergistic effect on cell viability. This synergistic action was also evident in an overadditive increase of caspase-3 and caspase-9 activity and the number of cells with dissipated Dc m , suggesting mitochondria to be a target of doxorubicin in SW403 cells. This phenomenon has also been recently described using short-chain pyridinium ceramides and doxorubicin in HepG2 cells (53) . However, in our hands, doxorubicin did not induce any alteration in endogenous ceramide levels in the cellular fractions analyzed (mitochondrial, cytosolic, and extramitochondrial). This is in contrast to several publications showing elevation of ceramide levels induced by anthracyclines (2, 34 -38) . Moreover, cotreatment of LCL-30 and doxorubicin did not result in an increase of mitochondrial S1P levels. These observations suggest that (a) the synergistic effect of doxorubicin and LCL-30 in SW403 cells is not founded on the level of sphingolipids and (b) the increase of S1P and the decrease of endogenous ceramide in mitochondria might be specifically related to the application of a mitochondrially targeted ceramide. However, further studies are needed to elucidate the precise mechanism of this drug synergism. Additionally, the exclusive mitochondrial alteration in sphingolipid levels has to be further explored using other mitochondriotoxic molecules.
There are some considerations that have to be taken into account while interpreting the results of this study. First, although LCL-30 was predominantly found in mitochondria, we cannot rule out the possibility that LCL-30 may also accumulate in other organelles, such as the endoplasmic reticulum and the Golgi, or might be gathered in microsomal membranes that tightly associate with mitochondria. However, there are no ultrastructural alterations of other organelles than mitochondria as identified in transmission electron microscopy. The destruction of mitochondrial architecture was the only pathologic finding, which suggests mitochondria to be the major target of cellular death executors induced by LCL-30. Second, the biochemical effects of LCL-30 have been extensively studied in only one cell line (human colon cancer cell line SW403). Different molecular pathways of cell death induction in other cancer cell lines cannot be excluded. However, LCL-30 was shown to induce cell death in a variety of other cancer cell lines (human colon carcinoma and hepatoma cell lines). Third, LCL-30 was not found to be toxic in freshly isolated hepatocytes. This finding supports the concept of selective toxicity of ceramides but does not answer the question of in vivo tolerability. Only animal studies, which are currently done by our group, may elucidate the role of LCL-30 or related compounds as a potential novel drug for cancer therapy.
In conclusion, we present a novel cationic long-chain pyridinium ceramide (LCL-30) causing apoptosis in a variety of cancer cells, including SW403 human colon cancer cells. In SW403, LCL-30 preferentially accumulated in mitochondria resulting in a selective decrease of the mitochondrial pool of endogenous ceramides. Moreover, we observed an increase of S1P in mitochondria, suggesting the presence of a mitochondrial sphingosine kinase. Alterations of mitochondrial sphingolipid levels might be interpreted as a regulated cellular defense mechanism against mitochondriotoxic drugs. Based on the numerous differences between mitochondria of normal and cancer cells, cationic long-chain pyridinium ceramides might be promising new drugs for cancer therapy by their mitochondrial preference. Furthermore, by the use of these novel ceramides, new insights might be gained into the function and regulation of mitochondrial sphingolipids. The efficacy and safety of LCL-30 is currently being tested in an animal model by our group.
